# The KEN SHE Study on HPV-vaccine Efficacy

> **NCT03675256** · PHASE4 · UNKNOWN · sponsor: **Massachusetts General Hospital** · enrollment: 2275 (actual)

## Conditions studied

- Papillomavirus Infections

## Interventions

- **BIOLOGICAL:** immediate Gardasil 9, delayed MenVeo vaccine
- **BIOLOGICAL:** immediate MenVeo vaccine, delayed Gardasil 9
- **BIOLOGICAL:** immediate Cervarix, delayed MenVeo vaccine

## Key facts

- **NCT ID:** NCT03675256
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-19
- **Primary completion:** 2024-02-15
- **Final completion:** 2024-02-15
- **Target enrollment:** 2275 (ACTUAL)
- **Last updated:** 2023-12-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03675256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03675256, "The KEN SHE Study on HPV-vaccine Efficacy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03675256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*